Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $27,500.00 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $5.50, for a total value of $27,500.00. Following the completion of the transaction, the insider directly owned 240,780 shares of the company’s stock, valued at approximately $1,324,290. This trade represents a 2.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total value of $24,750.00.
• On Monday, April 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.82, for a total value of $24,100.00.
• On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total value of $3,161.60.
• On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.96, for a total value of $7,936.00.
• On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.76, for a total value of $20,944.00.
• On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.68, for a total transaction of $17,433.00.
• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,152.94.
• On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Philippe Menu sold 2,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.87, for a total transaction of $11,688.00.
• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $13,095.00.

SOPHiA GENETICS Price Performance

Shares of NASDAQ:SOPH traded up $0.06 during midday trading on Friday, reaching $5.75. 423,880 shares of the company’s stock were exchanged, compared to its average volume of 174,550. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The company’s 50 day simple moving average is $5.06 and its two-hundred day simple moving average is $4.92. SOPHiA GENETICS SA has a 12 month low of $2.81 and a 12 month high of $5.94. The firm has a market capitalization of $482.37 million, a PE ratio of -11.06 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%. The business had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SOPH. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. BTIG Research restated a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and an average target price of $7.50.

Institutional Investors Weigh In On SOPHiA GENETICS

Several large investors have recently made changes to their positions in the company. Perkins Capital Management Inc. acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth about $49,000. Squarepoint Ops LLC acquired a new position in SOPHiA GENETICS in the third quarter valued at about $49,000. First Dallas Securities Inc. bought a new stake in SOPHiA GENETICS during the first quarter worth about $50,000. Quadrature Capital Ltd bought a new stake in SOPHiA GENETICS during the fourth quarter worth about $54,000. Finally, XTX Topco Ltd acquired a new stake in shares of SOPHiA GENETICS during the fourth quarter worth approximately $55,000. Institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.